Heather Wallace

Beacon Therapeutics

Daniel Chung

Beacon Therapeutics has appointed Daniel Chung as chief medical officer. Chung takes on the role after serving as chief medical officer at SparingVision. He was also previously ophthalmology therapeutic area leader at Spark Therapeutics and senior investigator at the FM Kirby Center for molecular ophthalmology at the University of Pennsylvania Perelman School of Medicine.

Veranova

Matteo Villain

Veranova has appointed Matteo Villain as vice president of peptides and oligonucleotides. Villain most recently served as vice president and global peptides technical lead at Piramal Pharma Solutions. He spent the majority of his 40-year career in positions of increasing responsibility at Bachem Americas, culminating in his role as vice president of CMC development.

STORM Therapeutics

Eric Martin

STORM Therapeutics has appointed Eric Martin as chief development officer. Martin has over 20 years of experience in oncology research and drug development, and more recently served as chief scientific officer at Arpeggio Biosciences. He also previously held senior leadership roles at companies including Pfizer Oncology, Kinnate Biopharma, Plexxikon and Ignyta.

Marea Therapeutics

Shishir Gadam

Marea Therapeutics has appointed Shishir Gadam as chief technical officer. Gadam joins the company from Cargo Therapeutics, where he also served as chief technical officer. Previously, he was vice president and head of cell therapy global manufacturing sciences and technology at Juno therapeutics, and held positions of increasing responsibility over more than a decade at Genentech.

Orca Bio

Steve Gavel

Orca Bio has appointed Steve Gavel as chief commercial officer. Gavel takes on the role after most recently serving as senior vice president, global cell therapy commercial development at Legend Biotech. He also previously led US commercial strategy and development at Celgene (now Bristol Myers Squibb), and held roles at Millennium Pharmaceuticals, IMS Health and Discovery Labs.

Abcuro

Courtney Cupples

Abcuro has appointed Courtney Cupples as chief commercial officer. Cupples most recently served as chief commercial officer for Priovant Therapeutics and previously spent nine years at Alexion Pharmaceuticals, culminating in her role as vice president, global metabolic franchise. She was also senior vice president, commercial strategy and marketing at Biohaven Pharmaceuticals.

Commit Biologics

Susan Kalled

Commit Biologics has appointed Susan Kalled as a member of its scientific advisory board. Kalled is an immunologist with over 25 years of experience. She previously served as chief scientific officer at Dianthus Therapeutics and Compass Therapeutics, and as vice president of biology at Q32 Bio. She has also held a number of leadership positions at Biogen and Shire.

Cancer Research Horizons

Ruth Plummer

Cancer Research Horizons has appointed Ruth Plummer as chair of its clinical advisory board. Plummer currently serves as clinical professor of experimental cancer medicine at Newcastle University, and leads a portfolio of trials across all phases of drug development. She is also an honorary consultant medical oncologist at Newcastle Hospitals NHS Foundation Trust.